HER2-directed therapy with Trastuzumab deruxtecan in recurrent mucinous ovarian carcinoma: complete clinical response and response to rechallenge

Gynecologic Oncology Reports · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles